Dewpoint launches with $60M series A to target biomolecular condensates

Dewpoint Therapeutics (Cambridge, Mass.) launched Jan. 30 with a $60 million series A round to fund development of its therapies targeting biomolecular condensates.

Condensates are cellular organelles that concentrate and organize proteins and nucleic acids, which can then enhance cell chemical reactions. Condensates are involved in multiple processes including RNA metabolism, ribosome biogenesis, DNA damage response and signal transduction...